Study towards improving artemisinin-based combination therapies

• Published in: Natural product reports Vol. 38; no. 7; p. 1243
• Main Authors: Lyu, Hai-Ning, Ma, Nan, Meng, Yuqing, Zhang, Xing, Wong, Yin-Kwan, Xu, Chengchao, Liao, Fulong, Jiang, Tingliang, Tu, Youyou, Wang, Jigang
• Format: Journal Article
• Language: English
• Published: England 21-07-2021
• Subjects: Antimalarials - therapeutic use; Artemisinins - therapeutic use; Drug Delivery Systems; Drug Therapy, Combination; Humans; Malaria - drug therapy; Molecular Structure
• ISSN: 1460-4752
• DOI: 10.1039/d0np00079e

Covering: Up to 2020 Artemisinin has made a significant contribution towards global malaria control since its initial discovery. Countless lives have been saved by this unique and miraculous molecule. In 2006, artemisinin-based combination therapies (ACTs) were recommended by the World Health Organization (WHO) as the first-line treatment for uncomplicated malaria infection and have since remained as the mainstays of the antimalarial treatment. Even so, substantial efforts to pursue better curative effects for the treatment of malaria have never ceased, particularly with regards to the circumstances surrounding the appearance of delayed clearance of malaria parasites by 3 day ACT treatments in South-East Asian countries. Strategies to further optimize artemisinin-based therapies, including synthesizing better artemisinin derivatives, developing advanced drug delivery systems, and diversifying artemisinin partner drugs, have been proposed over the past few years. Here, we provide an updated account of the continuous efforts in improving ACTs for better efficacy in curing malarial infection.